These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 8799313

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G, Morimoto S, Shiomi M.
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [Abstract] [Full Text] [Related]

  • 3. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y, Wada T, Shibouta Y, Ojima M, Sanada T, Ohtsuki K, Itoh K, Kubo K, Kohara Y, Naka T.
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells.
    Flesch M, Ko Y, Seul C, Düsing R, Feltkamp H, Vetter H, Sachinidis A.
    Eur J Pharmacol; 1995 Apr 28; 289(2):399-402. PubMed ID: 7621917
    [Abstract] [Full Text] [Related]

  • 9. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats.
    Kawamura M, Terashita Z, Okuda H, Imura Y, Shino A, Nakao M, Nishikawa K.
    J Pharmacol Exp Ther; 1993 Sep 28; 266(3):1664-9. PubMed ID: 8371164
    [Abstract] [Full Text] [Related]

  • 10. LC and LC-MS/TOF studies on stress degradation behaviour of candesartan cilexetil.
    Mehta S, Shah RP, Priyadarshi R, Singh S.
    J Pharm Biomed Anal; 2010 Jul 08; 52(3):345-54. PubMed ID: 19505786
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R, Högemann AM, Sunzel M, Riddell JG.
    J Hum Hypertens; 1997 Sep 08; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Candesartan cilexetil.
    Ardiana F, Lestari ML, Indrayanto G.
    Profiles Drug Subst Excip Relat Methodol; 2012 Sep 08; 37():79-112. PubMed ID: 22469317
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Determination of the site of glucuronidation in an N-(3,5-dichlorophenyl)succinimide metabolite by electrospray ionization tandem mass spectrometry following derivatization to picolinyl esters.
    Cui D, Harvison PJ.
    Rapid Commun Mass Spectrom; 2000 Sep 08; 14(21):1985-90. PubMed ID: 11085408
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.